We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Alnylam Pharmaceuticals, ...

The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche reported better than expected first-half operating profit, driven by strong sales of breast cancer and asthma ...

Some genetically targeted therapies are classified in the IRA as small-molecule drugs, limiting the incentive for biotech ...

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $2,138.15 today based on a price of $325.64 for ALNY at the time of writing.

The pharmaceutical industry has a fresh sense of direction after President Donald Trump’s tax-and-spending law included a ...

Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $357.7, a high estimate of $404.00, and a low estimate of $325.00. Marking an increase of 10.61%, the ...

Alnylam (Nasdaq: ALNY) has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults ...